Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors

Cumulative incidence of recurrent malignancy and NRM according to HCT CI and relapse risk categories. The combined groups of patients with MRDs and URDs were categorized according to the presence of pretransplantation comorbidities (HCT CI: 0, 1-2, or ≥ 3) [18] (A, B) and the predicted risk of recurrent malignancy (low, intermediate, or high) [35] (C, D). The cumulative incidence rates of recurrent malignancy (A, C) and NRM (B, D) are shown for respective subgroups of patients.

NRM, relapse or progression, and OS according to donor type. Cumulative incidence of NRM (A) and relapse or progression (B), and Kaplan-Meier survival estimates (C) in patients with HLA-identical sibling donors (“MRD,” n = 221) compared with those with URDs (“URD,” n = 184; P = .08). The third curve in each panel (“URD adjusted”) shows the projected survival with URDs after adjusting for HCT CI, relapse risk category, patient age, stem cell source, previous CMV infection, and donor–recipient sex mismatch.